FDAnews
www.fdanews.com/articles/113660-champions-concordia-establish-royalty-agreement-for-oncology-drug

Champions, Concordia Establish Royalty Agreement for Oncology Drug

January 12, 2009
Champions Biotechnology, Inc. announced that it has entered into a royalty agreement with Concordia Pharmaceuticals for the use of Salirasib, Concordia’s novel compound for the treatment of cancer, in combination with another targeted drug.
centredaily.com